Inosine Monophosphate Dehydrogenase Type II (IMPDH2) is a ubiquitously expressed dominant isoform during developmental stages. IMPDH2 gene is mapped to human chromosome 3p21.31.

Inosine Monophosphate Dehydrogenase Type II human has been used to test the inhibitory effect on vacor adenine dinucleotide (VAD) on its dehydrogenase activity.

Inosine Monophosphate Dehydrogenase Type II (IMPDH2) binds to adenosine triphosphate (ATP) and guanosine triphosphate (GTP). It catalyzes the formation of xanthosine monophosphate from inosine monophosphate in the presence of nicotinamide adenine dinucleotide (NAD). IMPDH2 elevated levels in tumors are correlated to its rate-limiting activity in guanosine monophosphate (GMP) synthesis. High levels of IMPDH2 is implicated in glioblastoma (GBM). It is regarded as a potential therapeutic target against tumors, antiviral, and immunosuppression-related pathologies.

Type II is the predominant IMPDH isoform and is specifically linked to a wide range of cancers and lymphocyte proliferation.

One unit will produce 1.0 μ mole of XMP from IMP with corresponding reduction of β-NAD per minute at pH 8.0 at 25 °C.

Solution in 20 mM Tris-HCl, pH 8.0, containing 0.5 mM EDTA and 1 mM DTT.